Navigation Links
New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood Vessel Damage Independent of Blood Pressure Lowering
Date:6/16/2008

Data published in the Journal of the American Society of Hypertension

demonstrate that early blockade of angiotensin II reversed vascular

hypertrophy

PARSIPPANY, N.J., June 16 /PRNewswire/ -- A new study published in the current Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, titled VIOS (Vascular Improvement with Olmesartan medoxomil Study) was a one-year, exploratory study that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.(1)

In the VIOS trial, olmesartan medoxomil, through early blockade of angiotensin II, improved the structure abnormalities of resistance arteries in patients with hypertension as measured by arterial wall to lumen ratio (W/L), returning arterial architecture to normal levels after one year of treatment. This protective effect was not seen with the comparator agent in the study, atenolol.(2) Olmesartan medoxomil is marketed in the United States by Daiichi Sankyo, Inc., as BENICAR(R). BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. BENICAR HCT is not indicated for initial therapy. BENICAR and BENICAR HCT have not been FDA approved for other indications such as end organ disease or other hypertension related morbidity.

"We believe the VIOS data add to the growing evidence for the role of angiotensin receptor blockers in preventing or reversing vascular damage at many stages during this disease process," said Carlos M. Ferrario, M.D., one of the study's lead inve
'/>"/>

SOURCE Daiichi Sankyo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. Pharmaxis Long-Term Safety Study of Bronchitol Completes
4. Iomai Announces Publication in The Lancet of Phase II Study Demonstrating Significant Efficacy of Travelers Diarrhea Vaccine
5. The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxters Cell-Based Pandemic, Avian Flu Vaccine
6. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
7. Genmab A/S - Company Announcement Ofatumumab in Subcutaneous Study in Rheumatoid Arthritis Summary: Subcutaneous Administration of Ofatumumab Investigated in Phase I/II Study
8. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
9. Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma
10. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
11. Banner Alzheimers Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , October 30, 2014 ... probiótico LGG contribuye a adquirir tolerancia a la ... alergia a la proteína de la leche de la ... primera infancia. Hasta ahora, la APLV se trataba ... se ha demostrado que es posible adquirir tolerancia ...
(Date:10/30/2014)... 2014  TWi Pharmaceuticals, Inc. today announced that it ... and Drug Administration (FDA) on its Abbreviated New Drug ... the generic equivalent to Eisai Inc.,s Aricept® 23mg.  Aricept® ... TWi Pharmaceuticals is preparing to launch the product ... Pharmaceuticals USA , at the earliest ...
(Date:10/30/2014)... 29, 2014 Electrodes are devices that ... be amplified to diagnose as well as treat ... medical devices facilitate the detection of chemical reactions ... and neurons of the patients. In addition, few ... alternating current to perform minimally invasive surgical procedures. ...
Breaking Medicine Technology:Según expertos reunidos en el Simposio Allergy Day 2Según expertos reunidos en el Simposio Allergy Day 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4
(Date:10/30/2014)... Paramount Rx, a full-service prescription benefits manager focused ... people save money through its innovative discount card program. ... in the new health care system, the Paramount Rx ... relationship between consumers, businesses and the pharmacy industry. ... today with medical costs is the rising price of ...
(Date:10/30/2014)... Home Care Assistance – Halton/Peel Region ... in-home senior care, is weighing in on a recent ... The study, performed by the University of Illinois, analyzed ... over a week-long period and observed how much time ... By examining the structural soundness of the white matter ...
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- When it comes to heart ... men to delay care when they have symptoms that spell ... to the hospital with a more severe or advanced stage ... study author Catherine Kreatsoulas, a Fulbright Scholar and research fellow ... news release from the Heart and Stroke Foundation of Canada. ...
(Date:10/30/2014)... Oct. 29, 2014 (HealthDay News) -- Eating a low-carb, ... to treat, according to new research. A ... modified Atkins diet, that focuses on foods like bacon, ... help reduce seizures in adults whose condition doesn,t improve ... 35 percent of people with epilepsy whose seizures are ...
Breaking Medicine News(10 mins):Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3
... PFCD Executive Director Ken Thorpe and Alan Aviles, ... York City Health and Hospitals Corporation, spoke to ... information technology (HIT) in the economic stimulus package. ... make the immediate investments necessary to ensure America,s ...
... for Children,s First Annual Awards CeremonyWASHINGTON, Jan. 14 ... Senators Richard Lugar (R-IN), Christopher Dodd (D-CT), Barbara ... Betty McCollum (D-MN-04) with the first annual GAC ... recognizes those who have done outstanding work on ...
... New research published in the January issue of the ... laparoscopic removal of gastrointestinal stromal tumors (GISTs) is safe and ... after an average follow-up time of three and a-half years. ... from special cells in the wall of the gastrointestinal tract ...
... who allegedly was seriously injured by Medtronic, Inc.,s Infuse(R) ... by Medtronic has sued the company, according to James ... LLC.The firms, along with co-counsel Lieff, Cabraser, Heimann & ... on behalf of Paul and Susan Antonelli, of Amsterdam, ...
... Jan. 14 Environmental Tectonics Corporation ... announced financial results for the third quarter and the first ... 2008. Thirteen weeks ended November 28, 2008 compared to thirteen ... a net loss of $113,000, or $0.04 per share (basic ...
... ARBOR, Mich. By the time they have been ... so impaired that they cannot give informed consent to ... left with the decision, but there is no clear ... research about the increasingly common disease is often stalled. ...
Cached Medicine News:Health News:PFCD Experts Cite Health Information Technology as Key Investment for Economic Stimulus 2Health News:Senators Lugar, Dodd, Boxer and Representatives Lee and McCollum Receive GAC Children's Champion Award 2Health News:Study shows surgery provides good long-term outcomes for patients with gastrointestinal cancers 2Health News:Medtronic, Inc. and Medtronic Sofamor Danek USA, Inc. Sued for Product Liability and Promoting the Off-Label Use of Infuse(R) Bone Graft Product, According to Page Perry, LLC 2Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 2Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 3Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 4Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 5Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 6Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 7Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 8Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 9Health News:Environmental Tectonics Corporation Announces Third Quarter and Year To Date Fiscal 2009 Results 10Health News:Most support Alzheimer's research based on family consent 2Health News:Most support Alzheimer's research based on family consent 3
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: